<DOC>
	<DOCNO>NCT00002602</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell may effective treatment prostate cancer . PURPOSE : Phase I/II trial study effectiveness radiation therapy treat patient previously untreated stage II stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose 3-dimensional conformal radiotherapy prostate gland immediately surround tissue patient stage II III adenocarcinoma prostate . II . Determine normal tissue toxicity rate regimen rectums bladder patient . III . Determine local control clinical pathologic examination PSA determination patient treat regimen . IV . Determine distant failure overall survival patient treat regimen . OUTLINE : This dose escalation study . Patients stratify accord 1 follow 3 prognostic group : Group 1 : T1b-c T2a-b combine PSA/Gleason ( CPG ) score 15 Group 2 : T1b-c T2a-b CPG score 15 , T2c PSA le 70 ng/mL Group 3 : T3 prostate specific antigen ( PSA ) less 70 ng/mL Patients receive 3-dimensional ( 3-D ) conformal radiotherapy 5 day week 7.6 , 8.2 , 8.8 week . Cohorts 120-270 patient receive escalate dos 3-D conformal radiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose precede 20 % patient experience dose-limiting toxicity . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 549-801 patient ( 120-204 patient first dose level , 237-321 patient second dose level , 192-276 patient third dose level ) accrue study within 4.75 5.25 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated adenocarcinoma prostate T1bc T2ab Gleason score 5 PSA great 4 ng/mL OR Any T3 PSA 70 ng/mL within 3 week prior entry least 10 day prostate biopsy No biopsy proven regional nodal involvement No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Hematopoietic : White blood cell ( WBC ) count least 4,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 11 g/dL Hepatic : Not specify Renal : Not specify Other : No major medical psychiatric illness would preclude study No malignancy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : Prior hormonal therapy allow Radiotherapy : No prior pelvic irradiation Surgery : No prior prostatectomy cryosurgery prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>